Serum microRNA-196 and microRNA-200 in pancreatic ductal adenocarcinoma of patients with diabetes mellitus
Jazyk angličtina Země Švýcarsko Médium print-electronic
Typ dokumentu časopisecké články
PubMed
27267055
DOI
10.1016/j.pan.2016.05.005
PII: S1424-3903(16)30073-4
Knihovny.cz E-zdroje
- Klíčová slova
- Biomarker, CA 19-9, Pancreatic cancer, miRNA,
- MeSH
- antigen CA-19-9 analýza MeSH
- diabetes mellitus genetika metabolismus MeSH
- duktální karcinom slinivky břišní komplikace genetika metabolismus MeSH
- glykovaný hemoglobin analýza MeSH
- hmotnostní úbytek MeSH
- komplikace diabetu * MeSH
- krevní glukóza analýza MeSH
- lidé středního věku MeSH
- lidé MeSH
- mikro RNA biosyntéza genetika MeSH
- nádory slinivky břišní komplikace genetika metabolismus MeSH
- prediabetes genetika metabolismus MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- antigen CA-19-9 MeSH
- glykovaný hemoglobin MeSH
- krevní glukóza MeSH
- mikro RNA MeSH
- MIRN196 microRNA, human MeSH Prohlížeč
- MIRN200 microRNA, human MeSH Prohlížeč
BACKGROUND/OBJECTIVES: Our aim was to compare expressions of 6 microRNAs (miRNAs) in patients with pancreatic ductal adenocarcinoma (PAC) and non-cancer patients, moreover according to the presence or absence of diabetes mellitus. METHODS: Expressions of miRNA-192, -196, -200, -21, -30 and -423 were measured in 77 patients with PAC and 64 non-cancer patients (34 patients with type 2 DM and 30 control persons). 60 patients with PAC (78%) had DM or prediabetes and it was of new-onset (less than 2 years before the cancer diagnosis) in 44 out of them. RESULTS: The expressions of all microRNAs were 1.4-3.7 times higher (significantly) in the PAC group compared to non-cancer patients. No difference was found between PAC diabetic and PAC non-diabetic patients. MicroRNA-200 was significantly higher in PAC patients with significant body weight loss against those without weight loss. Adding miRNA-196 and -200 to the current marker CA 19-9 improved the discriminative ability of the test (compared to CA 19-9 alone). CONCLUSION: MicroRNA-196 and -200 could be used as additional markers in PAC diagnosis.
Citace poskytuje Crossref.org
